兰克尔
骨转移
癌症研究
转移
免疫疗法
免疫
医学
乳腺癌
乳腺癌转移
癌症
抗体
癌细胞
内科学
激活剂(遗传学)
肿瘤科
免疫学
破骨细胞
转移性乳腺癌
主动免疫治疗
主动免疫
体外
癌症免疫疗法
受体
实验病理学
单克隆抗体
骨重建
免疫系统
作者
Bora Kim,Yong Jin Cho,Mineon Park,Wonbong Lim
标识
DOI:10.1097/cji.0000000000000393
摘要
Breast cancer cells often metastasize to bone. Accumulating evidence suggests that inhibiting the receptor activator of nuclear factor-κB ligand (RANKL) not only leads to reduced bone metastasis of breast cancer but also has antitumoral effects. Here, we used mutant receptor activator of nuclear factor-κB ligand (RANKLM) as a vaccine for active immunization to induce antibodies for immunotherapy of bone metastatic cancer. We investigated whether anti-RANKL antibodies inhibit osteolytic bone metastasis in vitro and in a murine model. MC3T3 cells stimulated by MDA-MB-231 culture medium secreted growth differentiation factor-15 (GDF-15), which induced the nuclear factor-κB signaling cascade. In addition, RANKLM treatment-induced reduction of intraosseous growth of MDA-MB-231 cells correlated with decreased GDF-15 expression, a reduced number of osteolytic lesions, and slower tumor progression. In addition, vaccination with RANKLM led to significant improvement in overall survival and skeletal metastasis in tumor-bearing mice. Induction of anti-RANKL antibodies by RANKLM decreased GDF-15 production by deactivating nuclear factor-κB signaling, which in turn inhibited metastasis of MDA-MB-231 cells to bone. Taken together, the results demonstrate a role for RANKLM immunization in preventing bone metastasis of breast cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI